» Articles » PMID: 15178579

Functional Characterization of Highly Purified Human Hematopoietic Repopulating Cells Isolated According to Aldehyde Dehydrogenase Activity

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2004 Jun 5
PMID 15178579
Citations 129
Authors
Affiliations
Soon will be listed here.
Abstract

Human hematopoietic stem cells (HSCs) are commonly purified by the expression of cell surface markers such as CD34. Because cell phenotype can be altered by cell cycle progression or ex vivo culture, purification on the basis of conserved stem cell function may represent a more reliable way to isolate various stem cell populations. We have purified primitive HSCs from human umbilical cord blood (UCB) by lineage depletion (Lin(-)) followed by selection of cells with high aldehyde dehydrogenase (ALDH) activity. ALDH(hi)Lin(-) cells contained 22.6% +/- 3.0% of the Lin(-) population and highly coexpressed primitive HSC phenotypes (CD34(+) CD38(-) and CD34(+)CD133(+)). In vitro hematopoietic progenitor function was enriched in the ALDH(hi)Lin(-) population, compared with ALDH(lo)Lin(-) cells. Multilineage human hematopoietic repopulation was observed exclusively after transplantation of ALDH(hi)Lin(-) cells. Direct comparison of repopulation with use of the nonobese diabetic/severe combined immunodeficient (NOD/SCID) and NOD/SCID beta2 microglobulin (beta2M) null models demonstrated that 10-fold greater numbers of ALDH(hi)-Lin(-) cells were needed to engraft the NOD/SCID mouse as compared with the more permissive NOD/SCID beta2M null mouse, suggesting that the ALDH(hi)Lin(-) population contained committed progenitors as well as primitive repopulating cells. Cell fractionation according to lineage depletion and ALDH activity provides a viable and prospective purification of HSCs on the basis of cell function rather than cell surface phenotype.

Citing Articles

Distinct Phenotypic and Molecular Characteristics of CD34 and CD34 Hematopoietic Stem/Progenitor Cell Subsets in Cord Blood and Bone Marrow Samples: Implications for Clinical Applications.

Gaafar A, Hamza F, Yousif R, Shinwari Z, Alotaibi A, Iqniebi A Diagnostics (Basel). 2025; 15(4).

PMID: 40002599 PMC: 11853955. DOI: 10.3390/diagnostics15040447.


Aldehyde Dehydrogenase, a Marker of Normal and Malignant Stem Cells, Typifies Mesenchymal Progenitors in Perivascular Niches.

Gomez-Salazar M, Wang Y, Thottappillil N, Hardy R, Alexandre M, Holler F Stem Cells Transl Med. 2023; 12(7):474-484.

PMID: 37261440 PMC: 10651226. DOI: 10.1093/stcltm/szad024.


Cell therapy in end-stage liver disease: replace and remodel.

Hu X, Chen L, Wu H, Tang Y, Zheng Q, Wei X Stem Cell Res Ther. 2023; 14(1):141.

PMID: 37231461 PMC: 10210428. DOI: 10.1186/s13287-023-03370-z.


Isolation and characterization of circulating pro-vascular progenitor cell subsets from human whole blood samples.

Terenzi D, Bakbak E, Trac J, Al-Omran M, Quan A, Teoh H STAR Protoc. 2021; 2(1):100311.

PMID: 33554145 PMC: 7856468. DOI: 10.1016/j.xpro.2021.100311.


Expression of NR5A2, NUP153, HNF4A, USP15 and FNDC3B is consistent with their use as novel biomarkers for bovine mammary stem/progenitor cells.

Choudhary R, Capuco A J Mol Histol. 2021; 52(2):289-300.

PMID: 33400051 DOI: 10.1007/s10735-020-09948-8.